Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Prasopporn S, et al. Among authors: ponvilawan b. Front Oncol. 2023 Jan 6;12:1124912. doi: 10.3389/fonc.2022.1124912. eCollection 2022. Front Oncol. 2023. PMID: 36686801 Free PMC article.
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia.
Kubota Y, Zawit M, Durrani J, Shen W, Bahaj W, Kewan T, Ponvilawan B, Mori M, Meggendorfer M, Gurnari C, LaFramboise T, Feurstein S, Sekeres MA, Visconte V, Godley LA, Haferlach T, Maciejewski JP. Kubota Y, et al. Among authors: ponvilawan b. Leukemia. 2022 Dec;36(12):2827-2834. doi: 10.1038/s41375-022-01729-4. Epub 2022 Oct 20. Leukemia. 2022. PMID: 36266327
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.
Suppramote O, Prasopporn S, Aroonpruksakul S, Ponvilawan B, Makjaroen J, Suntiparpluacha M, Korphaisarn K, Charngkaew K, Chanwat R, Pisitkun T, Okada S, Sampattavanich S, Jirawatnotai S. Suppramote O, et al. Among authors: ponvilawan b. Front Oncol. 2022 May 17;12:877194. doi: 10.3389/fonc.2022.877194. eCollection 2022. Front Oncol. 2022. PMID: 35664774 Free PMC article.
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Prasopporn S, et al. Among authors: ponvilawan b. Front Oncol. 2022 Nov 30;12:1021632. doi: 10.3389/fonc.2022.1021632. eCollection 2022. Front Oncol. 2022. PMID: 36531039 Free PMC article.
Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Kungwankiattichai S, Ponvilawan B, Roy C, Tunsing P, Kuchenbauer F, Owattanapanich W. Kungwankiattichai S, et al. Among authors: ponvilawan b. Front Med (Lausanne). 2022 Feb 15;9:801632. doi: 10.3389/fmed.2022.801632. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35242779 Free PMC article.
Effects of different types of allogeneic hematopoietic stem cell transplantation donors on Philadelphia chromosome-positive acute lymphoblastic leukemia during the tyrosine kinase inhibitor era: A systematic review and meta-analysis.
Ponvilawan B, Owattanapanich W, Charoenngam N, Kungwankiattichai S. Ponvilawan B, et al. Hematol Oncol Stem Cell Ther. 2023 Apr 4;16(3):197-208. doi: 10.1016/j.hemonc.2021.09.007. Hematol Oncol Stem Cell Ther. 2023. PMID: 34743893 Free article.
63 results